Literature DB >> 16985927

Overview of prostate-specific membrane antigen.

Sam S Chang.   

Abstract

Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target. The radio-immunoconjugate form of the anti-PSMA monoclonal antibody 7E11 is used in the commercially available and US Food and Drug Administration-approved diagnostic tool, the ProstaScint(R) (Cytogen Corporation, Princeton, NJ) scan. Recent studies have demonstrated other possible useful roles for PSMA as a target, not only in prostate cancer, but in other malignancies.

Entities:  

Year:  2004        PMID： 16985927      PMCID： PMC1472940     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  49 in total

1.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

2.  Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.

Authors:  D Kahn; R D Williams; D W Seldin; J A Libertino; M Hirschhorn; R Dreicer; G J Weiner; D Bushnell; J Gulfo
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

3.  Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).

Authors:  M L Salgaller; P A Lodge; J G McLean; B A Tjoa; D J Loftus; H Ragde; G M Kenny; M Rogers; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1998-05       Impact factor: 4.104

4.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Authors:  G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

5.  Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis.

Authors:  A Khan; V J Caride
Journal:  Urology       Date:  2000-07-01       Impact factor: 2.649

6.  Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Authors:  Samuel R Denmeade; Lori J Sokoll; Susan Dalrymple; D Marc Rosen; Alyssa M Gady; Debra Bruzek; Rebecca M Ricklis; John T Isaacs
Journal:  Prostate       Date:  2003-03-01       Impact factor: 4.104

7.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.

Authors:  R E Carter; A R Feldman; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

9.  Detection of a non-Hodgkin's lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma.

Authors:  Italo Zanzi; Richard Stark
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

10.  Prostate-specific membrane antigen: evidence for the existence of a second related human gene.

Authors:  J Leek; N Lench; B Maraj; A Bailey; I M Carr; S Andersen; J Cross; P Whelan; K A MacLennan; D M Meredith
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640
View more
  109 in total

Review 1.  Bispecific T-cell engagers for cancer immunotherapy.

Authors:  Amelia M Huehls; Tiffany A Coupet; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

2.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.

Authors:  C A S Regino; K J Wong; D E Milenic; E H Holmes; K Garmestani; P L Choyke; M W Brechbiel
Journal:  Curr Radiopharm       Date:  2009-01

Review 4.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

5.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

6.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Authors:  Liran Domachevsky; Natalia Goldberg; Hanna Bernstine; Meital Nidam; David Groshar
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

7.  Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.

Authors:  Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Donika Plyku; Zora Nováková; Mary Brummet; Bryan Wharram; Cyril Barinka; Robert Hobbs; Martin G Pomper
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

8.  Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.

Authors:  Kar Muthumani; Liron Marnin; Sagar B Kudchodkar; Alfredo Perales-Puchalt; Hyeree Choi; Sangya Agarwal; Veronica L Scott; Emma L Reuschel; Faraz I Zaidi; Elizabeth K Duperret; Megan C Wise; Kimberly A Kraynyak; Kenneth E Ugen; Niranjan Y Sardesai; J Joseph Kim; David B Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-17       Impact factor: 6.968

9.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

10.  Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer.

Authors:  Waseem Hariri; Thangirala Sudha; Dhruba J Bharali; Huadong Cui; Shaker A Mousa
Journal:  Pharm Res       Date:  2015-03-12       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.